On this snowy start to 2022, I wanted to share with you two interviews with AHEAD100 Chief Scientist Dr. James Crowe that occurred over the last week on CNBC and Bloomberg TV. Each piece is a powerful continuation of our work to build awareness and support for the work of the Global Pandemic Prevention and Biodefense Center and lead initiative, AHEAD100 — and together, they garnered more than 100 million impressions, representing more than $1 million in advertising value equivalent.
Dr. James Crowe, Director of the Vanderbilt Vaccine Center and Chief Scientist of Ahead100 described the benefits of monoclonal antibody treatment to Paul Sweeney and Matt Miller on "Bloomberg Markets: America."
Dr. James Crowe, Chief Scientist of AHEAD100, joins CNBC's “Squawk Box” to discuss the development of monoclonal antibody treatments for Covid.
We'd appreciate your help in spreading the word on both of these among your networks: here's a LinkedIn post and tweet with the CNBC piece, as well as a LinkedIn post and tweet with the Bloomberg piece. Please share and retweet!
As we continue our work together to build the case of monoclonal antibodies as a critical part of the arsenal to continue to fight COVID, as well as their power in preventing the next pandemic before it starts, we're grateful for your guidance and leadership.